

SC5b-9 antibody [3R2/0]

Cat. No. GTX39131

Host	Mouse
Clonality	Monoclonal
Isotype	lgG2b
Applications	WB, IHC-Fr, FCM, ELISA
Reactivity	Human

Package 100 μg

Applications

Application Note

*Optimal dilutions/concentrations should be determined by the researcher.

Suggested dilution	Recommended dilution
WB	Assay dependent
IHC-Fr	Assay dependent
FCM	Assay dependent
ELISA	Assay dependent

Not tested in other applications.

Product Note

This antibody recognizes the SC5b-9 complex of around 330 kDa. Both the classical and alternative complement pathways result in the formation of the cytolysis inducing C5b-9 complex. This complex is composed of 190 kDa C5b, which is bound to cells via 71 kDa C9. Sublytic assembly of C5b-9 on plasma membranes induces cell cycle activation and survival. The binding of C5b-9 to the 75 kDa S-protein (or vitronectin) in the fluid phase prevents C5b-9 from assembling on the plasma membrane, deactivating it and forming the SC5b-9 complex. SC5b-9 is stable in vitro and is, therefore, a reliable indicator of terminal complement pathway activation.

Liquid
Borate buffered saline
0.1% Sodium azide
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4°C. For long-term storage, aliquot and store at -20°C or below. Avoid multiple freeze-thaw cycles.
1.0 mg/ml (Please refer to the vial label for the specific concentration.)
Protein A purified
Unconjugated



For full product information, images and publications, please visit our website.

Date 2025 / 12 / 16 Page 1 of 2



For laboratory research use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.

Note

Purchasers shall not, and agree not to enable third parties to, analyze, copy, reverse engineer or otherwise attempt to determine the structure or sequence of the product.



For full product information, images and publications, please visit our website.

Date 2025 / 12 / 16 Page 2 of 2